Scientists at Wake Forest School of Medicine have identified a dead probiotic that reduces age-related leaky gut in older mice. The study is published in the journal GeroScience.
Currently over 6,300 people in the UK are waiting for an organ transplant, and sadly everyday around three people die waiting. In efforts to reduce the reliance on organ donors and improve the outlook for patients, alternative sources of organs are being explored by several research groups.
In a study recently published in Nature Biomedical Engineering, bioengineered livers created by decellularization and recellularization were implanted into pigs, where they were able to sustain continuous perfusion for up to 15 days. We spoke to Miromatrix’s CEO, Dr Jeff Ross, to learn more about the study and how it advances the state of bioengineering organs.
Anna MacDonald (AM): What are some of the main challenges faced when creating bioengineered organs?
Lancaster University researchers have discovered, for the first time, how a genetic alteration that increases the risk of developing Autism and Tourette’s impacts on the brain.
Their research also suggests that ketamine, or related drugs, may be a useful treatment for both of these disorders.
Autism affects an estimated 2.8 million people in the UK while Tourette’s Syndrome — a condition that causes a person to make involuntary sounds and movements called tics –affects an estimated 300,000 people in the UK. The treatments available for both disorders are limited and new treatments are urgently required. Recent research has also shown that these disorders are genetically linked.
Led by researchers at Baylor College of Medicine, a study published in the journal Cell Stem Cell reveals a new mechanism that contributes to adult bone maintenance and repair and opens the possibility of developing therapeutic strategies for improving bone healing.
“Adult bone repair relies on the activation of bone stem cells, which still remain poorly characterized,” said corresponding author Dr. Dongsu Park, assistant professor of molecular and human genetics and of pathology and immunology at Baylor. “Bone stem cells have been found both in the bone marrow inside the bone and also in the periosteum—the outer layer of tissue—that envelopes the bone. Previous studies have shown that these two populations of stem cells, although they share many characteristics, also have unique functions and specific regulatory mechanisms.”
Of the two, periosteal stem cells are the least understood. It is known that they comprise a heterogeneous population of cells that can contribute to bone thickness, shaping and fracture repair, but scientists had not been able to distinguish between different subtypes of bone stem cells to study how their different functions are regulated.
I am in shock… Google suddenly as yahoo are allowing conjecture and mendacity be seen as public or scientific opinion. Here is another confused mind who towards the end of her rant quotes Christian scripture as basis to stop Life extension-Transhumanism???
When I say to these minds Behold the leader of Christianity stood for Life abundant-Super Longevity and I can prove such. No matter what lost evangelist or preacher tells you Jesus was a medical researcher of extraordinary magnitude…
NOW BEHOLD THE LOST in this article… https://www.rodofironministries.com/…/transhumanism-and-imm… Respect r.p.berry & AEWR wherein aging now ends we have found the many causes of aging and we have located an expensive cure. We search for partners-investors to now join us in agings end… gerevivify.blogspot.com/
College Freshman, Bailey O’Brien beat Stage 4 Melanoma at CHIPSA Hospital in 2011! The cancer she thought she beat, had come back with a vengeance. She had 7 inoperable tumors and doctors at Sloan Kettering only gave her months to live. Refusing this death sentence, her parents ventured to CHIPSA for treatment: https://chipsahospital.org/how-bailey-obrien-beat-the-odds-a…-hospital/
Your gastrointestinal system contains about a hundred trillion bacteria. That may sound scary, but it’s actually beneficial because these bacteria help with digestion, immunity and other important functions.
Even though they are basically helpful, the bacteria can go astray in disagreeable ways.
Small intestinal bacterial overgrowth (SIBO) is a condition where otherwise beneficial bacteria end up in the wrong part of the digestive system, then proliferate and cause unpleasant symptoms such as abdominal pain, gas, bloating, constipation and diarrhea.
Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.
The therapy is known is MS1943. In a cancer cell line and mouse models, it degraded a protein called EZH2 that drives the growth of triple-negative breast cancer.
Research teams led by Jian Jin, Ph.D., Director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, Ph.D., Director of The Tisch Cancer Institute at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. They also showed that agents that inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple-negative breast cancer.
Cancer immunology drugs, which harness the body’s immune system to better attack cancer cells, have significantly changed the face of cancer treatment. People with aggressive cancers are now living longer, healthier lives. Unfortunately, cancer immunology therapy only works in a subset of patients.
Now, a new study from scientists at the UCLA Jonsson Comprehensive Cancer Center helps explain why some people with advanced cancer may not respond to one of the leading immunotherapies, PD-1 blockade, and how a new combination approach may help overcome resistance to the immunotherapy drug.
The UCLA study, published today in the inaugural issue of the new scientific journal Nature Cancer, showed that genetic and pharmacological inhibition of the oncogene PAK4 overcomes resistance to anti-PD-1 therapy in preclinical models.
